Is it safe to use smoking cessation therapeutics during pregnancy?

Expert Opinion on Drug Safety

Volumn 13, Issue 12, 2014, Pages 1721-1731

  De Long, Nicole E ^a   Barra, Nicole G ^a   Hardy, Daniel B ^b   Holloway, Alison C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bupropion; E cigarettes; Nicotine replacement therapy; Varenicline

Indexed keywords

AMFEBUTAMONE; COLLAGEN; ELECTRONIC CIGARETTE; FIBRONECTIN; NICOTINE; VARENICLINE; BENZAZEPINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ADDICTION; ASTHMA; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD BEHAVIOR; CLINICAL STUDY; DEPRESSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FETUS OUTCOME; GLUCOSE INTOLERANCE; HEART FUNCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MATERNAL SERUM; MATERNAL SMOKING; METABOLIC DISORDER; NEWBORN DEATH; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PLACENTA CIRCULATION; POSTNATAL CARE; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; REVIEW; SMALL FOR DATE INFANT; SMOKING CESSATION; SPONTANEOUS ABORTION; STILLBIRTH; TOBACCO DEPENDENCE; UNCERTAINTY; VENTRAL TEGMENTUM; ANIMAL; FEMALE; PROCEDURES; SMOKING; THERAPY;

ANIMALS; BENZAZEPINES; BUPROPION; FEMALE; HUMANS; PREGNANCY; QUINOXALINES; SMOKING; SMOKING CESSATION;

EID: 84912000368     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.973846     Document Type: Review

References (130)

1. Aliyu MH, Lynch O, Wilson RE, et al. Association between tobacco use in pregnancy and placenta-Associated syndromes: A population-based study. Arch Gynecol Obstet 2011;283(4):729-34
2. Pineles BL, Park E, Samet JM. Systematic review and meta-Analysis of miscarriage and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol 2014;179(7):807-23
3. Zhang K, Wang X. Maternal smoking and increased risk of sudden infant death syndrome: A meta-Analysis. Leg Med (Tokyo) 2013;15(3):115-21
4. Tong VT, Dietz PM, Morrow B, et al. Trends in smoking before, during, and after pregnancy-pregnancy risk assessment monitoring system, united states, 40 sites, 2000-2010. MMWR Surveill Summ 2013;62(6):1-19
5. Cui Y, Shooshtari S, Forget EL, et al. Smoking during pregnancy: findings from the. 2009-2010 Canadian Community Health Survey. PLoS One 2014;9(1):e84640
6. Jimenez Ruiz CA. Nicotine replacement therapy during pregnancy. Arch Bronconeumol 2006;42(8):404-9
7. Kaneita Y, Tomofumi S, Takemura S, et al. Prevalence of smoking and associated factors among pregnant women in Japan. Prev Med 2007;45(1):15-20
8. Mohsin M, Bauman AE. Socio-demographic factors associated with smoking and smoking cessation among 426,344 pregnant women in New South Wales. Australia. BMC Public Health 2005;5:138
9. Tappin DM, MacAskill S, Bauld L, et al. Smoking prevalence and smoking cessation services for pregnant women in Scotland. Substance Abuse Treat Prev Policy 2010;5:1
10. Ruggiero L, Tsoh JY, Everett K, et al. The transtheoretical model of smoking: comparison of pregnant and nonpregnant smokers. Addict Behav 2000;25(2):239-51
11. England LJ, Kendrick JS, Wilson HG, et al. Effects of smoking reduction during pregnancy on the birth weight of term infants. Am J Epidemiol 2001;154(8):694-701
12. Orton S, Bowker K, Cooper S, et al. Longitudinal cohort survey of women's smoking behaviour and attitudes in pregnancy: study methods and baseline data. BMJ Open 2014;4(5):e004915
13. WHO. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. WHO Guidelines Approved by the Guidelines Review Committee, Geneva; 2013
14. American college of obstetricians and gynecologists. Smoking cessation during pregnancy. Committee Opinion No. 471. Obstet Gynecol 2010.116:1241-4. Available from: www. acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Smoking-Cessation-During-Pregnancy [Last accessed 11 September 2014]
15. PHS Guideline update panel liaisons, and staff. treating tobacco use and dependence: 2008 update U.S. Public health service clinical practice guideline executive summary. Respir Care 2008;53(9):1217-22
16. Chamberlain C, O'Mara-Eves A, Oliver S, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev 2013;10:CD001055
17. Benowitz N, Dempsey D. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res 2004;6(Suppl 2):S189-202
18. Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med 2000;9(3):270-81
19. Ontario Medical Association. Rethinking stop-smoking medications: treatment myths and medical realities. [update 2008]. Ont Med Rev 2008;75(1):22-34
20. Peters MJ, Morgan LC. The pharmacotherapy of smoking cessation. Med J Aust 2002;176(10):486-90
21. Raw M, Regan S, Rigotti NA, McNeill A. A survey of tobacco dependence treatment services in 36 countries. Addiction 2009;104(2):279-87
22. Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol 2014;77(2):324-36
23. Phelan S. Smoking cessation in pregnancy. Obstet Gynecol Clin North Am 2014;41(2):255-66
24. Coleman T, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2012;9:CD010078
25. Rustemeier K, Stabbert R, Haussmann HJ, et al. Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke. Food Chem Toxicol 2002;40(1):93-104
26. Swauger JE, Steichen TJ, Murphy PA, Kinsler S. An analysis of the mainstream smoke chemistry of samples of the U.S. Cigarette market acquired between 1995 and 2000. Regul Toxicol Pharmacol 2002;35(2 Pt 1):142-56
27. Glynn DA, Cryan JF, Kent P, et al. Update on smoking cessation therapies Adv Ther 2009;26(4):369-82
28. Dwoskin LP, Smith AM, Wooters TE, et al. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 2009;78(7):732-43
29. Luck W, Nau H, Hansen R, Steldinger R. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther 1985;8(6):384-95
30. Luck W, Nau H. Nicotine and cotinine concentrations in the milk of smoking mothers: influence of cigarette consumption and diurnal variation. Eur J Pediatr 1987;146(1):21-6
31. Bruin JE, Gerstein HC, Holloway AC. Long-term consequences of fetal and neonatal nicotine exposure: A critical review. Toxicol Sci 2010;116(2):364-74
32. Ginzel KH, Maritz GS, Marks DF, et al. Critical review: nicotine for the fetus, the infant and the adolescent J Health Psychol 2007;12(2):215-24
33. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents Neurotoxicol Teratol 2008;30(1):1-19
34. Wang D, Connock M, Barton P, et al. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: A systematic review of effectiveness and economic analysis. Health Technol Assess 2008;12(2):iii-iv ix-xi 1-135
35. Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: Systematic review and meta-Analysis. Addiction 2011;106(1):52-61
36. Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: A randomized controlled study. Obstet Gynecol 2000;96(6):967-71
37. Berlin I, Grange G, Jacob N, Tanguy ML. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014;348:g1622
38. Hotham ED, Gilbert AL, Atkinson ER. A randomised-controlled pilot study using nicotine patches with pregnant women. Addict Behav 2006;31(4):641-8
39. Pollak KI, Oncken CA, Lipkus IM, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med 2007;33(4):297-305
40. Coleman T, Cooper S, Thornton JG, et al. A randomized trial of nicotinereplacement therapy patches in pregnancy. N Engl J Med 2012;366(9):808-18
41. Oncken C, Dornelas E, Greene J, et al. Nicotine gum for pregnant smokers: A randomized controlled trial. Obstet Gynecol 2008;112(4):859-67
42. Bowker KA, Lewis S, Coleman T, et al. Comparison of cotinine levels in pregnant women while smoking and when using nicotine replacement therapy. Nicotine Tob Res 2014;16(6):895-8
43. Brose LS, McEwen A, West R. Association between nicotine replacement therapy use in pregnancy and smoking cessation. Drug Alcohol Depend 2013;132(3):660-4
44. von Kries R, Toschke AM, Koletzko B, Slikker WMaternal smoking during pregnancy and childhood obesity. Am J Epidemiol 2002;156(10):954-61
45. CAN-ADAPTT. Canadian smoking cessation clinical practice guideline. canadian action network for the advancement, dissemination and adoption of practice-informed tobacco treatment, centre for addiction and mental health. Toronto, Canada; 2011. Available from: informahealthcare. com/userimages/ContentEditor/1232541144107/Guidelines-EODC.pdf [Last accessed 11 September 2014]
46. Ministry of Health. New Zealand Smoking Cessation Guidelines. Ministry of Health, Wellington, New Zealand. 2007. Available from: www.treatobacco. net/en/uploads/documents/Treatment% 20Guidelines/New%20Zealand% 20treatment%20guidelines%20in% 20English%202007.pdf [Last accessed 11 September 2014]
47. ASAM. Utilisation des traitements de substitution nicotinique (TSN) chez les femmes enceintes-Point deìnformation-epoint dètape. Agence nationale de sècuritè du medicament et des produits de sant-e. 2007. Available from: http://ansm.sante. fr/S-informer/Points-d-information-Points-d-information/Utilisation-destraitements-de-substitution-nicotinique-TSN-chez-les-femmes-enceintes-Point-dinformation-point-d-etape [Last accessed 11 September 2014]
48. NICE. Quitting smoking during pregnancy and following childbirth. National Institute for Health and Care Excellence. 2010. Available from: www.nice.org.uk/guidance/ph26/chapter/recommendations#recommendation-5-use-ofnrt-And-other-pharmacologicalsupport [Last accessed 11 September 2014]
49. Merritt T, Mazela J, Merritt A. Tobacco smoking and its consequences on reproductive health: the impact of a lifestyle choices including cigarette smoke exposure on fertility and birth defects. Przegl Lek 2013;70(10):779-83
50. Koch S, Vilser C, Gross W, Schleussner E. [smoking during pregnancy: Risk for intrauterine growth retardation and persisting microsomia]. Z Geburtshilfe Neonatol 2012;216(2):77-81
51. Forinash AB, Pitlick JM, Clark K, Alstat V. Nicotine replacement therapy effect on pregnancy outcomes. Ann Pharmacother 2010;44(11):1817-21
52. Milidou I, Henriksen TB, Jensen MS, et al. Nicotine replacement therapy during pregnancy and infantile colic in the offspring. Pediatrics 2012;129(3):e652-8
53. Lassen TH, Madsen M, Skovgaard LT. Maternal use of nicotine replacement therapy during pregnancy and offspring birth weight: A study within the Danish National Birth Cohort. Paediatr Perinat Epidemiol 2010;24(3):272-81
54. Ma N, Nicholson CJ, Wong M, et al. Fetal and neonatal exposure to nicotine leads to augmented hepatic and circulating triglycerides in adult male offspring due to increased expression of fatty acid synthase. Toxicol Appl Pharmacol 2014;275(1):1-11
55. Schneider T, Ilott N, Brolese G, et al. Prenatal exposure to nicotine impairs performance of the 5-choice serial reaction time task in adult rats. Neuropsychopharmacology 2011;36(5):1114-25
56. Behl M, Rao D, Aagaard K, et al. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: A national toxicology program workshop review. Environ Health Perspect 2013;121(2):170-80
57. Duijts L. Fetal and infant origins of asthma. Eur J Epidemiol 2012;27(1):5-14
58. Harding R, Maritz G. Maternal and fetal origins of lung disease in adulthood. Semin Fetal Neonatal Med 2012;17(2):67-72
59. Petre MA, Petrik J, Ellis R, et al. Fetal and neonatal exposure to nicotine disrupts postnatal lung development in rats: role of VEGF and its receptors. Int J Toxicol 2011;30(2):244-52
60. Shi W, Bellusci S, Warburton D. Lung development and adult lung diseases. Chest 2007;132(2):651-6
61. Sekhon HS, Jia Y, Raab R, et al. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. J Clin Invest 1999;103(5):637-47
62. Sekhon HS, Proskocil BJ, Clark JA, Spindel ER. Prenatal nicotine exposure increases connective tissue expression in foetal monkey pulmonary vessels. Eur Respir J 2004;23(6):906-15
63. Wongtrakool C, Wang N, Hyde DM, et al. Prenatal nicotine exposure alters lung function and airway geometry through alpha7 nicotinic receptors. Am J Respir Cell Mol Biol 2012;46(5):695-702
64. Wongtrakool C, Grooms K, Ping XD, et al. In utero nicotine exposure promotes m2 activation in neonatal mouse alveolar macrophages. Pediatr Res 2012;72(2):147-53
65. Gratchev A, Guillot P, Hakiy N, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaig-h3. Scand J Immunol 2001;53(4):386-92
66. Sekhon HS, Keller JA, Benowitz NL, et al. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med 2001;164:989-94
67. Rehan VK, Asotra K, Torday JS. The effects of smoking on the developing lung: insights from a biologic model for lung development, homeostasis, and repair. Lung 2009;187:281-9
68. Dasgupta C, Xiao D, Xu Z, et al. Developmental nicotine exposure results in programming of alveolar simplification and interstitial pulmonary fibrosis in adult male rats. Reprod Toxicol 2012;34:370-7
69. Rehan VK, Liu J, Naeem E, et al. Perinatal nicotine exposure induces asthma in second generation offspring. BMC Med 2012;10:129
70. Cooper S, Taggar J, Lewis S, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, doubleblind, placebo-controlled snap trial. Lancet Respir Med 2014;2:728-37
71. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 2004;6:S125-40
72. Thiering E, Bruske I, Kratzsch J, et al. Prenatal and postnatal tobacco smoke exposure and development of insulin resistance in 10 year old children. Int J Hyg Environ Health 2011;214:361-8
73. Weng SF, Redsell SA, Swift JA, et al. Systematic review and meta-Analyses of risk factors for childhood overweight identifiable during infancy. Arch Dis Child 2012;97:1019-26
74. Bruin JE, Kellenberger LD, Gerstein HC, et al. Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. J Endocrinol 2007;194:171-8
75. Lim R, Sobey CG. Maternal nicotine exposure and fetal programming of vascular oxidative stress in adult offspring. Br J Pharmacol 2011;164:1397-9
76. Xiao D, Huang X, Yang S, et al. Estrogen normalizes perinatal nicotineinduced hypertensive responses in adult female rat offspring. Hypertension 2013;61:1246-54
77. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry 2001;40:630-41
78. DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. Pediatrics 2004;113:1007-15
79. Zhu JL, Olsen J, Liew Z, et al. Parental smoking during pregnancy and ADHD in children: the Danish national birth cohort. Pediatrics 2014;134:e382-8
80. Sengupta SM, Fortier ME, Thakur GA, et al. Parental psychopathology in families of children with attentiondeficit/hyperactivity disorder and exposed to maternal smoking during pregnancy. J Child Psychol Psychiatry 2014;doi: 10.1111/jcpp.12286
81. Holz NE, Boecker R, Baumeister S, et al. Effect of prenatal exposure to tobacco smoke on inhibitory control: neuroimaging results from a 25-year prospective study. JAMA Psychiatry 2014;71:786-96
82. Parameshwaran K, Buabeid MA, Karuppagounder SS, et al. Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus. Cell Mol Life Sci 2012;69:829-41
83. Schneider T, Bizarro L, Asherson PJ, et al. Hyperactivity, increased nicotine consumption and impaired performance in the five-choice serial reaction time task in adolescent rats prenatally exposed to nicotine. Psychopharmacology (Berl) 2012;223:401-15
84. Eppolito AK, Bachus SE, McDonald CG, et al. Late emerging effects of prenatal and early postnatal nicotine exposure on the cholinergic system and anxiety-like behavior. Neurotoxicol Teratol 2010;32:336-45
85. Zhu J, Zhang X, Xu Y, et al. Prenatal nicotine exposure mouse model showing hyperactivity, reduced cingulate cortex volume, reduced dopamine turnover, and responsiveness to oral methylphenidate treatment. J Neurosci 2012;32:9410-18
86. Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. Pharmacol Ther 2009;122:125-39
87. Buka SL, Shenassa ED, Niaura R. Elevated risk of tobacco dependence among offspring of mothers who smoked during pregnancy: A 30-year prospective study. Am J Psychiatry 2003;160:1978-84
88. Cornelius MD, Leech SL, Goldschmidt L, et al. Prenatal tobacco exposure: is it a risk factor for early tobacco experimentation Nicotine Tob Res 2000;2:45-52
89. Stroud LR, Papandonatos GD, Shenassa E, et al. Prenatal glucocorticoids and maternal smoking during pregnancy independently program adult nicotine dependence in daughters: A 40-year prospective study. Biol Psychiatry 2013;75:47-55
90. Mantella NM, Kent PF, Youngentob SL. Fetal nicotine exposure increases preference for nicotine odor in early postnatal and adolescent, but not adult. rats. PLoS One 2013;8:e84989
91. Mizrak S, Turan V, Terek MC, et al. The effect of long term nicotine exposure on nicotine addiction and fetal growth. J Turk Ger Gynecol Assoc 2012;13:237-41
92. Liu L, Liu F, Kou H, et al. Prenatal nicotine exposure induced a hypothalamic-pituitary-Adrenal axisassociated neuroendocrine metabolic programmed alteration in intrauterine growth retardation offspring rats. Toxicol Lett 2012;214:307-13
93. Harrod SB, Lacy RT, Morgan AJ. Offspring of prenatal IV nicotine exposure exhibit increased sensitivity to the reinforcing effects of methamphetamine. Front Pharmacol 2012;3:116
94. Franke RM, Park M, Belluzzi JD, et al. Prenatal nicotine exposure changes natural and drug-induced reinforcement in adolescent male rats. Eur J Neurosci 2008;27:2952-61
95. Hiscock R, Goniewicz ML, McEwen A, et al. E-cigarettes: online survey of UK smoking cessation practitioners. Tob Induc Dis 2014;12:13
96. Bertholon JF, Becquemin MH, Annesi-Maesano I, et al. Electronic cigarettes: A short review. Respiration 2013;86:433-8
97. Burstyn I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 2014;14:18
98. Schober W, Szendrei K, Matzen W, et al. Use of electronic cigarettes (ecigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers. Int J Hyg Environ Health 2014;217:628-37
99. Orr KK, Asal NJ. Efficacy of electronic cigarettes for smoking cessation. Ann Pharmacother 2014;48(11):1502-06
100. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl) 2014;231:401-7
101. Etter JF, Bullen C. Saliva cotinine levels in users of electronic cigarettes. Eur Respir J 2011;38:1219-20
102. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 2013;15:267-70
103. Electronic nicotine delivery systems. WHO framework convention on tobacco control. Moscow, Russia: conference of the parties to the WHO framework convention on tobacco control. 2014. Available from: http://apps.who. int/gb/fctc/PDF/cop6/FCTC-COP6-10-en.pdf [Last accessed 11 September 2014]
104. Zhu SH, Gamst A, Lee M, et al. The use and perception of electronic cigarettes and snus among the U.S. population. PLoS One 2013;8:e79332
105. Odum LE, O'Dell KA, Schepers JS. Electronic cigarettes: do they have a role in smoking cessation J Pharm Pract 2012;25:611-14
106. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-5
107. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103
108. Xi ZX. Preclinical pharmacology, efficacy and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug Healthc Patient Saf 2010;2010:39-48
109. Le Houezec J, Aubin HJ. Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opin Pharmacother 2013;14:1959-67
110. Champix (varenicline tartrate tablets): Pfizer Canada Inc. Pfizer, Quebec, Canada 2014. Available from: www.pfizer.ca/en/our-products/products/monograph/152 [Last accessed 11 September 2014]
111. NICE: how to stop smoking in pregnancy and following childbirth. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence, London, UK; 2010. Available from: www.nice.org.uk/guidance/ph26 [Last accessed 11 September 2014]
112. Treating tobacco use and dependence: 2008 update. Tobacco use and dependence guideline panel. US department of health and human services; Rockville, MD: 2008. Available from: www.ncbi.nlm.nih. gov/books/NBK63952/[Last accessed 11 September 2014]
113. Myung SK, Ju W, Jung HS, et al. Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: A meta-Analysis. BJOG 2012;119:1029-39
114. Harrison-Woolrych M, Paterson H, Tan M. Exposure to the smoking cessation medicine varenicline during pregnancy: A prospective nationwide cohort study. Pharmacoepidemiol Drug Saf 2013;22:1086-92
115. Wellbutrin label and approval history; U. S. food and drug administration center for drug evaluation and research. FDA/U.S. Department of Health & Human Service, Silver Spring, MD; 2007. Available from: www.accessdata. fda.gov/drugsatfda-docs/nda/2006/021928-s000-Chantix-PharmR.pdf [Last accessed 11 September 2014]
116. Kaplan YC, Olgac Dundar N, Kasap B, et al. Pregnancy outcome after varenicline exposure in the first trimester. Case Rep Obstet Gynecol 2014;2014:263981
117. Zyban (bupropion hydrochloride) sustained-release tablets, for oral use. GlaxoSmithKline,Research Triangle Park, NC: 2014. Available from: www.gsksource.com/gskprm/htdocs/documents/ZYBAN-PI-MG.PDF [Last accessed 11 September 2014]
118. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-7
119. Rigotti NA, Park ER, Chang Y, et al. Smoking cessation medication use among pregnant and postpartum smokers. Obstet Gynecol 2008;111:348-55
120. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf 2014;doi: 10.1002/pds.3661
121. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol 2008;198:e191-5
122. Alwan S, Reefhuis J, Rasmussen SA, et al. Patterns of antidepressant medication use among pregnant women in a united states population. J Clin Pharmacol 2011;51:264-70
123. Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 2005;24:19-23
124. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol 2005;192:932-6
125. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:474-84
126. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6
127. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203:52-e51-6
128. De Long N, Hyslop JR, Nicholson CJ, et al. Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. Reprod Sci 2013;20:1156-61
129. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010;40:1723-33
130. Reynolds LP, Caton JS, Redmer DA, et al. Evidence for altered placental blood flow and vascularity in compromised pregnancies. J Physiol 2006;572:51-8